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There are still no effective treatments to prevent, halt, or reverse Alzheimer’s disease, but research
advances over the past three decades could change this gloomy picture. Genetic studies demon-
strate that the disease has multiple causes. Interdisciplinary approaches combining biochemistry,
molecular and cell biology, and transgenic modeling have revealed some of its molecular mecha-
nisms. Progress in chemistry, radiology, and systems biology is beginning to provide useful
biomarkers, and the emergence of personalized medicine is poised to transform pharmaceutical
development and clinical trials. However, investigative and drug development efforts should be
diversified to fully address the multifactoriality of the disease.Introduction
Alzheimer’s disease (AD) is characterized by progressive loss of
memory and other cognitive functions. Typically, a decade or so
passes before the illness has taken its course and patients die in
a completely helpless state. The long duration of AD and its
attack on the fragile structures that harbor the very essence of
who we are place an enormous emotional and financial burden
on patients, their families, and society. AD is estimated to have
cost the world $604 billion in 2010 alone (Wimo and Prince,
2010). These costs are staggering, particularly in light of predic-
tions that the worldwide number of AD cases, currently esti-
mated at 36 million, will triple by 2050 (Wimo and Prince,
2010). Few health care systems will be able to cope with this
development. This Review highlights some of the most informa-
tive developments in AD research and raises major unresolved
issues.
Substrates of Cognitive Decline
AD causes a large loss in brain weight and volume and affects
some brain regions and neuronal populations more than others
(Go´mez-Isla et al., 1996). Although AD clearly causes loss of
neurons in specific brain regions (e.g., of pyramidal cells in
lamina II of the entorhinal cortex and in the CA1 region of the
hippocampus), much of the overall loss of brain volume appears
to be due to the shrinkage and loss of neuronal processes.
Progress in radiological imaging techniques has advanced
morphometric measurements from postmortem tissues to live
patients (Hampel et al., 2010). For example, progressive
decreases in cortical thickness can be detected in multiple brain
regions by magnetic resonance imaging (MRI) in AD patients,
correlate with cognitive decline, and predict conversion from
mild cognitive impairment (MCI) to AD (Frisoni et al., 2010;
Putcha et al., 2011). Consequently, this measure is increasingly
used in the early diagnosis of AD and as a biomarker in clinical
trials.1204 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Beyond such anatomical alterations, functional MRI (fMRI) has
revealed alterations in neural network activities in patients with
AD and people at risk for developing the disease. These include
abnormal activity and connectivity in the so-called default mode
network, which in healthy people is most active when they do not
think about anything in particular, and hyperactivation of the
hippocampus during the execution of memory tasks (Sperling
et al., 2010), which correlates with decreased hippocampal
volume and abnormal cortical thinning in AD-vulnerable brain
regions (Putcha et al., 2011). Consistent with electrophysiolog-
ical and biochemical data obtained in related transgenic mouse
models (Palop and Mucke, 2010; Verret et al., 2012), these
observations suggest that AD does not simply silence neurons
and neural networks, but rather causes aberrant network activity
that might actively interfere with the intricate processes under-
lying learning, memory and other cognitive functions. In addition,
overstimulation of specific neuronal populations could result in
excitotoxicity, which likely contributes to neurodegeneration in
AD and related conditions. It is interesting in this regard that
AD is associated with an increased incidence of epileptic
seizures, which ismost evident in patients with early-onset forms
of the disease (Palop and Mucke, 2009). Findings in transgenic
mouse models suggest that these complications may be the
tip of an iceberg, representing an escalation of more subtle alter-
ations of neural network activity (Palop and Mucke, 2010; Verret
et al., 2012).
Much evidence suggests that synapses and dendrites, the
specializations through which neurons send and receive signals,
respectively, are particularly vulnerable to AD. Loss of synapses
and dendritic spines correlates better with cognitive decline in
AD than loss of neurons (Palop et al., 2006). Synaptodendritic
rarefaction is also observed in neuronal cultures and in brains
of transgenic mice exposed to factors suspected of causing
AD. In thesemodels, the degeneration is preceded by alterations
in synaptic function and aberrant network activity (Marchetti and
Figure 1. Multifactorial Basis of Alzheimer’s Disease Pathogenesis
(A) Alzheimer’s disease (AD) is likely to be caused by copathogenic interactions among multiple factors, including APP/Ab, apoE4, tau, a-synuclein, TDP-43,
aging, and various comorbidities. How exactly they conspire to impair neuronal functions and survival remains to be determined.
(B) Aggregation and accumulation of Ab in the brain may result from increased production of Ab, decreased degradation by Ab-degrading enzymes, or reduced
clearance across the blood-brain barrier. Ab oligomers impair synaptic functions and related signaling pathways, changing neuronal activities, and trigger the
release of neurotoxic mediators from glial cells. Fibrillar amyloid plaques displace and distort neuronal processes. The lipid transport protein apoE4 impairs Ab
clearance and promotes Ab deposition. When expressed within stressed neurons, apoE4 is cleaved, to a much greater extent than apoE3, into neurotoxic
fragments that disrupt the cytoskeleton and impair mitochondrial functions. Tau, which is normally most abundant in axons, becomes mislocalized to the
neuronal soma and dendrites and forms inclusions called neurofibrillary tangles (NFTs). a-synuclein can also self-assemble into pathogenic oligomers and form
larger aggregates (Lewy bodies). Both tau and a-synuclein can also be released into the extracellular space, where they may spread to other cells. Vascular
abnormalities impair the supply of nutrients and removal of metabolic byproducts, cause microinfarcts, and promote the activation of glial cells.Marie, 2011; Palop and Mucke, 2010), suggesting that these
types of dysfunction are early manifestations of the disease
and, possibly, also contribute to its progression.
Recent advances in radiological imaging have also enabled
the detection of pathological hallmarks of AD in live patients,
improving diagnostic accuracy and patient selection for clinical
trials. After injection into the blood stream, Pittsburg compound
B (PIB) traverses the blood-brain barrier (BBB) and binds to
deposits of fibrillar amyloid-b (Ab) peptides (amyloid plaques),
whose abnormal accumulation in brain is a requirement for the
pathological diagnosis of AD. PIB binding to amyloid plaques
can be detected by positron emission tomography (PET).
A multitude of other radiopharmaceutical probes are being
developed for the detection of plaques or neurofibrillary tangles
(NFTs) (Kim et al., 2010), another pathological hallmark of AD.
While the detection of these pathological hallmarks in live
patients clearly has diagnostic value, it is still uncertain whether
these hallmarks actually contribute to cognitive dysfunction in
AD and whether they represent useful outcome measures for
clinical trials. Plaque loads determined histopathologically or
radiologically do not correlate well with functional impairments,
as illustrated most strikingly by people with substantial plaque
burdens and normal cognition (Giannakopoulos et al., 2003).
Recent studies have demonstrated an association between
increased PIB binding and development of AD 5 years later
(Morris et al., 2009), which has been interpreted as a likely
cause-effect relationship. However, some cases with autosomal
dominant AD show high levels of PIB binding in the basal ganglia
but no greater propensity to develop extrapyramidal motorimpairments, indicating dysfunction of these brain regions,
than cases with sporadic AD, who have different distributions
of PIB binding (Villemagne et al., 2009).
Furthermore, inheritance of the E693D mutation in Ab, which
inhibits formation of insoluble amyloid fibrils and promotes the
formation of soluble Ab oligomers, causes a syndrome that
closely resembles AD clinically but does not appear to be asso-
ciated with significant increases in cerebral PIB binding (Shi-
mada et al., 2011). Additionally, the pattern of PIB accumulation
differs between patients with sporadic late-onset AD and
patients with APP locus duplication (Remes et al., 2008). These
observations and a large body of data obtained in transgenic
mouse models (Palop et al., 2006; Palop and Mucke, 2010)
caution against the interpretation that plaques are the main
cause and plaque-associated neuritic dystrophy the main
substrate of cognitive decline in AD. Although NFTs correlate
more closely with cognitive decline in AD than plaques (Gianna-
kopoulos et al., 2003), results obtained in transgenic mouse
models indicate that NFTs do not necessarily impair neuronal
function and that the microtubule-associated protein tau, the
main constituent of NFTs, can cause neuronal dysfunction
independently of these structures, as reviewed in (Morris et al.,
2011).
Taken together, these studies suggest that aberrant neural
network activity, dysfunction and loss of synapses, and degen-
eration of specific neuronal populations are the main substrates
of cognitive decline in AD. As outlined below, it is likely that
these abnormalities are caused by copathogenic interactions
among diverse factors and pathways (Figure 1).Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1205
Multifactional Etiology of AD
Genetics, Epigenetics, and Epidemiology
AD is probably caused by complex interactions among multiple
genetic, epigenetic, and environmental factors. Mutations in
three genes—amyloid precursor protein (APP), presenilin
(PS)-1 and PS-2—cause early-onset (<60 years) autosomal
dominant AD (Bertram et al., 2010), which probably accounts
for less than 1% of AD cases (Campion et al., 1999). The muta-
tions affect APP processing, leading to altered production of
different Ab peptides and, thus, their relative ratios (Bertram
et al., 2010). Down’s syndrome patients carrying an extra copy
of chromosome 21, on which the APP gene resides, develop
early-onset dementia with pathological hallmarks of AD in their
brains (Millan Sanchez et al., 2011), consistent with the idea
that overexpression of APP causes early-onset AD. In strong
support of this notion, duplication of the APP gene alone leads
to early-onset AD (Rovelet-Lecrux et al., 2006). Moreover,
increased APP gene expression caused by genetic variations
in the promoter sequence may be a risk factor for late-onset
AD, with levels of APP expression correlating inversely with
age of disease onset (Brouwers et al., 2006).
Apolipoprotein (apo) E4 (used here to refer to either the APOE
ε4 allele or the protein it encodes) has been genetically linked to
late-onset (>60 years) familial and sporadic AD, which accounts
for most AD cases, and has a gene-dose effect on increasing the
risk and lowering the age of onset of the disease (Corder et al.,
1993; Farrer et al., 1997). All well-conducted genome-wide
association studies (GWASs) on late-onset AD from different
populations around the world identified apoE4 as the top late-
onset AD gene with extremely high confidence (Bertram et al.,
2010). Remarkably, the lifetime risk estimate of developing AD
for individuals with two copies of the apoE4 allele (2% of the
population) is 60% by the age of 85, and for those with one
copy of the apoE4 allele (25% of the population) 30%. In
comparison, the lifetime risk of AD for those with two copies of
the apoE3 allele is 10% by the age of 85. Thus, apoE4 should
be considered a major gene, with semidominant inheritance, for
late-onset AD (Genin et al., 2011). A recent GWAS also identified
apoE4 as the only significant gene associated with age-related
cognitive decline in humans (De Jager et al., 2011), which is in
line with a longitudinal study showing that age-related memory
decline in nondemented apoE4 carriers diverges from that of
nondemented noncarriers before the age of 60 years (Caselli
et al., 2009). Thus, apoE4’s detrimental effect on cognition
occurs before the typical signs of AD arise. In contrast, apoE2
may protect against AD in some populations (Farrer et al.,
1997). GWAS also identified other genes that modulate the risk
of late-onset AD, including CLU, CR1, PICALM, BIN1, SORL1,
GAB2, ABCA7, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and
HLA-DRB1/5 (Bertram et al., 2010; Logue et al., 2011). However,
the relative contribution of these genes to AD is modest as
compared to apoE4.
Epigenetic mechanisms may also play a role in AD pathogen-
esis (Day and Sweatt, 2011). Studies on human postmortem
brain samples and peripheral leukocytes, as well as transgenic
animal models, have shown that aging and AD are associated
with epigenetic dysregulation at various levels, including
abnormal DNA methylation and histone modifications (Choulia-1206 Cell 148, March 16, 2012 ª2012 Elsevier Inc.ras et al., 2010). Although it is unclear whether the epigenetic
changes observed in AD represent a cause or a consequence
of the disease, twin studies support the notion that epigenetic
mechanisms modulate AD risk (Chouliaras et al., 2010). Interest-
ingly, pharmacological inhibition of DNA methylation in the
hippocampus after a learning task impaired memory consolida-
tion in mice (Day and Sweatt, 2011), and promotion of histone
acetylation improved learning and memory in a mouse model
of AD and increased learning-related gene expression in aged
wild-type mice (Fischer et al., 2007; Peleg et al., 2010), suggest-
ing epigenetic regulation of learning and memory in health and
disease.
Aging is the most important known nongenetic risk factor for
late-onset AD. Potential environmental risk factors for late-onset
AD include head injury, low educational levels, hyperlipidemia,
hypertension, homocysteinemia, diabetes mellitus, and obesity
(Barnes and Yaffe, 2011; Rosendorff et al., 2007; Sharp and
Gatz, 2011; Van Den Heuvel et al., 2007). However, several of
these associations remain controversial (Daviglus et al., 2010).
Combinations of apoE4 with one or more of these environmental
risk factors may further increase the risks for late-onset AD and
age-related cognitive decline (Caselli et al., 2011; Haan et al.,
1999).
Ab and Other APP Products
Ab peptides, the main constituent of amyloid plaques, and
various other metabolites are derived from APP by proteolytic
cleavage (Citron, 2010; De Strooper et al., 2010). Diverse lines
of evidence support the hypothesis that APP and Ab contribute
causally to the pathogenesis of AD (Figure 2). Overexpression
of APP in humans through duplication of its gene or trisomy of
chromosome 21 causes early-onset AD (see above), whereas
partial trisomy 21 excluding the APP gene does not (Prasher
et al., 1998). The catalytic subunit of the g-secretase protein
complex that releases Ab peptides from its precursor is formed
by PS1 or PS2. Autosomal dominant mutations in APP, PS1, or
PS2 that alter APP processing and the production or self-
aggregation of Ab, promoting aggregation and accumulation
of Ab in brain cause early-onset AD (Bertram et al., 2010).
Neuronal expression of mutant human APP (hAPP) either alone
or in combination with mutant PS1 in transgenic rodents causes
several AD-like alterations, as reviewed previously (Ashe and
Zahs, 2010; Jucker, 2010; Marchetti and Marie, 2011; Palop
and Mucke, 2010; Querfurth and LaFerla, 2010) and described
further below.
Several lines of evidence suggest that Ab regulates neuronal
and synaptic activities and that accumulation of Ab in the brain
causes an intriguing combination of aberrant network activity
and synaptic depression (Figure 2A) (Palop and Mucke, 2010).
Impairments of inhibitory interneurons and aberrant stimulation
of glutamate receptors, which can result in excitotoxicity, appear
to play important upstream roles in this pathogenic cascade
(Figures 2B and 2C) (Meilandt et al., 2008; Palop and Mucke,
2010; Sanchez-Mejia et al., 2008; Verret et al., 2012). Aberrant
neuronal activity might trigger a vicious cycle by augmenting Ab
production,which is regulated, at least inpart, byneuronal activity
(Bero et al., 2011). The immediate early gene Arc, which directly
binds to PS1 to regulate g-secretase trafficking, is required for
neuronal activity-dependent Ab production (Wu et al., 2011).
Figure 2. Ab in AD Pathogenesis and Related Therapeutic Strategies
(A) Pathogenic Ab assemblies cause tau-dependent aberrant excitatory network activity and synaptic depression, which may lead directly, or indirectly through
hippocampal remodeling, to cognitive dysfunction. Identification and blockade of the upstream mechanisms that trigger this cascade are important objectives.
(B) Ab-dependent aberrant network activity may be caused by impairments of inhibitory interneurons resulting from depletion of voltage-gated sodium channel
subunits (VGSC), intracellular activities of neurotoxic apoE4 fragments, or elevated metenkephalin (Enk) levels. Additional mechanisms that may cause neuronal
overexcitation in AD include impairment of glutamate transporters (e.g., GLT1), resulting in decreased clearance of glutamate (Glu), and increased neuronal or
microglial production of factors that promote excitotoxicity, including arachidonic acid (AA) and quinolinic acid (Quin).
(C) hAPP mice have depletions of the VGSC subunit Nav1.1 that impair the function of parvalbumin (PV)-positive inhibitory interneurons (PV cells), resulting in
reduced intensity of gamma oscillations and network hypersynchrony. These network abnormalities can be prevented by increasing Nav1.1 levels in PV cells (1)
and counteracted, at least temporarily, by behavioral interventions that enhance gamma activity (2).
(D) Ab may impair neuronal functions by receptor-mediated and receptor-independent mechanisms. Potential therapeutic strategies include (1) lowering Ab
production with secretase inhibitors or modulators and enhancing Ab clearance with antibodies or activation of Ab-degrading enzymes, (2) blocking the inter-
action of Ab with cell surface receptors, and (3) modulating downstream pathways to make the brain more resistant against whatever Ab cannot be removed
effectively and safely.Results obtained in diverse experimental models suggest that
insoluble Ab fibrils found in amyloid plaques and monomeric Ab
are less pathogenic than soluble, nonfibrillar assemblies of Ab
such as Ab dimers, trimers, and larger oligomers (Figure 1B).
However, which Ab assemblies are most pathogenic and how
their accumulation in brain causes synaptic and neuronal
dysfunction are unresolved topics of intense study and debate
(Benilova et al., 2012; Li et al., 2011; Palop and Mucke, 2010).
These moieties may act extracellularly and intracellularly and
engage proteins as well as lipids. Several cell-surface molecules
have been implicated in Ab oligomer-induced toxicity (Fig-
ure 2D), including the receptor tyrosine kinase EphB2 (Cisse´
et al., 2011) and the receptor for advanced glycation end prod-
ucts (Srikanth et al., 2011). Potential downstream mechanisms
include changes in the distribution or activity of neurotransmitterreceptors and related signaling molecules (Jo et al., 2011; Li
et al., 2011; Palop andMucke, 2010; Renner et al., 2010; Ro¨nicke
et al., 2011), disruption of intracellular calcium homeostasis (Ca-
mandola and Mattson, 2011), and impairments of axonal trans-
port and mitochondrial functions (Decker et al., 2010; Du et al.,
2008; Querfurth and LaFerla, 2010; Sheng and Cai, 2012; Vossel
et al., 2010).
A major current obstacle in the field is the lack of techniques to
reliably quantify the abundance of soluble Ab assemblies in brain
tissues, particularly on neuronal membranes. This problem has
precluded correlations of cognitive impairments in AD patients
with levels of these assemblies in strategic sites. It has also
made it impossible to know whether any of the Ab-related drugs
that underwent clinical trials actually lowered the levels of func-
tionally relevant Ab assemblies in AD-vulnerable brain regions.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1207
Figure 3. ApoE4 in AD Pathogenesis and Related Therapeutic Strategies
(A) ApoE4 probably has both Ab-dependent and Ab-independent roles in AD pathogenesis. ApoE4 impairs Ab clearance and promotes Ab deposition (left). In
addition, neuronal apoE4 undergoes proteolytic cleavage to generate neurotoxic fragments, contributing to AD pathogenesis independently of Ab (right).
(B) The apoE proteolysis hypothesis suggests that, in response to stresses or injuries, neuronal apoE expression is triggered to facilitate neuronal repair. However,
neuronal apoE undergoes proteolytic cleavage, with apoE4 being more susceptible to the cleavage than apoE3, resulting in the formation of neurotoxic frag-
ments. The apoE4 fragments enter the cytosol and cause tau pathology and mitochondrial impairment. Hilar GABAergic interneurons in the dentate gyrus are
particularly vulnerable to apoE4 fragment toxicity and the resulting impairments contribute to learning and memory deficits.
(C) Neuronal expression of apoE and apoE proteolysis-related neurotoxicity represent targets for the development of novel therapeutics. Inhibiting apoE4
expression in neurons should reduce the level of toxic apoE4 fragments and their downstreamdetrimental effects. Identification of the protease that cleaves apoE
in neurons should enable the development of specific protease inhibitors to reduce the production of neurotoxic apoE fragments. It may also be possible to
develop drugs to protect mitochondria and the cytoskeleton from attack by the toxic apoE fragments.Other uncertainties about the value of Ab-lowering drugs relate
to the potential physiological functions of APP and different
APP metabolites, including Ab (Duce et al., 2010; Giuffrida
et al., 2009; Lee et al., 2010b; Puzzo et al., 2011; Weyer et al.,
2011; Yang et al., 2009) and to the question of whether APP itself
or APP metabolites other than Ab (e.g., the C-terminal fragments
C99, intracellular domain, or C31) also contribute to the patho-
genesis of AD (Ghosal et al., 2009; Harris et al., 2010; Simo´n
et al., 2009).
ApoE4
The major impact of apoE4 on AD risk is clearly at odds with the
relatively small amount of attention it has received in the field, as
compared to, for instance, APP, Ab, tau, and inflammation. To
encourage improvement of this situation, we will review the
pathobiology of apoE4 in greater depth here. Since apoE4 was
identified as a genetic risk factor for AD, in vitro and in vivo
studies have explored its structural properties and functions in
neurobiology, its cellular source-dependent physiological and
pathophysiological activities in brain, and its Ab-dependent
and independent roles in AD pathogenesis (Figure 3).
ApoE Polymorphisms and Functions in Neurobiology. ApoE is
a polymorphic protein with three common isoforms, apoE2,
apoE3, and apoE4, in humans. The three isoforms differ from
one another by single-amino acid substitutions (Mahley et al.,
2006). ApoE has important and diverse roles in neurobiology
(Bu, 2009; Huang, 2006; Kim et al., 2009; Mahley et al., 2006).
It has isoform-specific roles in neurite remodeling: apoE3 stimu-
lates neurite outgrowth, and apoE4 inhibits it (Huang, 2006,
2010; Mahley et al., 2006). ApoE also takes up lipids generated
after neuronal degeneration and redistributes them to cells
requiring lipids for proliferation, membrane repair, or remyelina-
tion of new axons (Huang, 2006; Mahley et al., 2006). Synaptic1208 Cell 148, March 16, 2012 ª2012 Elsevier Inc.and dendritic alterations are observed in apoE-deficient mice
(Masliah et al., 1995) and transgenic mice expressing apoE4
in neurons (Buttini et al., 1999). In addition, apoE modulates
glutamate receptor function and synaptic plasticity by regulating
apoE receptor recycling in neurons, with apoE3 stimulating and
apoE4 inhibiting this process (Chen et al., 2010).
Interaction between the N- andC-terminal domains is a unique
biophysical property of apoE4 (Zhong and Weisgraber, 2009).
Crystallographic and other biophysical studies revealed that
this domain interaction is mediated by a salt bridge formation
between Arg-61 and Glu-255 (Zhong and Weisgraber, 2009).
Mutation of Arg-61 to threonine or of Glu-255 to alanine in
apoE4 prevents domain interaction and makes apoE4 more
apoE3-like (Zhong and Weisgraber, 2009). The domain inter-
action is responsible for impaired intraneuronal trafficking of
apoE4 (Brodbeck et al., 2011), apoE4’s susceptibility to proteol-
ysis (Huang, 2010; Mahley et al., 2006), apoE4-induced impair-
ments in neurite outgrowth, and mitochondrial functions
(Brodbeck et al., 2011; Chen et al., 2012), and apoE4-associated
astrocytic dysfunction (Zhong and Weisgraber, 2009).
Cellular Source-DependentRolesof apoE4 inADPathogenesis.
ApoE derived from different cellular sources has distinct roles
in both physiological and pathophysiological pathways (Huang,
2006, 2010; Mahley et al., 2006). Astrocytes have long been
recognized as the primary source of apoE in the brain, and
expression of apoE in astrocytes is increased during aging and
in response to estrogen and activation of liver X receptor or NF-
kB (Huang, 2006, 2010; Mahley et al., 2006). In vitro and in vivo
studies suggest that astrocyte-derived apoE has isoform-
specific effects on Ab clearance or deposition (Kim et al., 2009),
neurite outgrowth (Holtzman et al., 1995), and behavioral perfor-
mance (Hartman et al., 2001).
Central nervous system neurons also express apoE, but
mostly in response to stresses and injuries (Huang, 2006; Xu
et al., 2006). Interestingly, astrocyte-conditioned medium upre-
gulates apoE expression in neurons, and this regulation is
controlled by intron-3 retention/splicing of the apoE gene
through the extracellular signal-regulated kinase pathway (Harris
et al., 2004; Xu et al., 2008). Neuron-derived apoE3 and apoE4
differ in their intracellular trafficking (Brodbeck et al., 2011), their
susceptibility to proteolysis (Brecht et al., 2004), and their effects
on mitochondrial function (Chang et al., 2005; Chen et al., 2012),
tau phosphorylation (Brecht et al., 2004), lysosomal (Ji et al.,
2002) and neuronal integrity (Buttini et al., 1999), androgen
receptor levels (Raber et al., 2002), and cognitive functions
(Raber et al., 1998). Interestingly, when expressed in neurons,
apoE3 is excitoprotective, whereas apoE4 is not; however,
when expressed in astrocytes, apoE3 and apoE4 are equally ex-
citoprotective (Buttini et al., 2010). Thus, the cellular source of
apoE markedly affects its physiological and pathophysiological
activities. One potential mechanism underlying these differential
effects is apoE4 proteolysis, which generates neurotoxic frag-
ments and occurs in neurons but not in astrocytes (Huang, 2010).
Ab-Dependent Roles of apoE4 in AD Pathogenesis. In vivo,
apoE is associated with amyloid plaques and in vitro lipid-free
apoE3 and apoE4 can form stable complexes with Ab peptides,
with apoE4 forming complexes more rapidly and effectively
(Huang, 2006; Kim et al., 2009). Studies in apoE-deficient mice
expressing mutant hAPP demonstrate that apoE is actually
required for the formation of fibrillar amyloid plaques (Bales
et al., 1999; Holtzman et al., 2000). However, when incubated
with Ab peptides, lipidated apoE3 and apoE4 yield different
results. ApoE3 binds Ab with a 20-fold greater affinity than
apoE4, suggesting that lipidated apoE differs from lipid-free
apoE in its ability to interact with Ab peptides (Huang, 2006;
Kim et al., 2009). Interestingly, decreasing apoE’s lipidation
status by knockout of ABCA1 in mice expressing mutant hAPP
significantly increases brain amyloid loads, whereas increasing
apoE lipidation status by overexpression of ABCA1 decreases
amyloid levels (Kim et al., 2009). Thus, altering apoE lipidation
changes its ability tomediate Ab clearance or deposition in brain.
In hAPP transgenic mice, human apoE stimulates Ab clear-
ance. ApoE2 and apoE3 clear more Ab than apoE4 (Bales
et al., 1999; Holtzman et al., 2000), which may be related to
apoE isoform-dependent effects on astroglial degradation of
Ab deposits (Koistinaho et al., 2004). Measuring Ab clearance
rates by microdialysis in the brains of hAPP transgenic mice
expressing apoE3 or apoE4 revealed that apoE4 decreases Ab
clearance by about 40% compared to apoE3 (Castellano et al.,
2011). A recent study demonstrated that C-terminally truncated
apoE4, which is found in AD brains, inefficiently clears Ab and
acts in concert with Ab to elicit neuronal and behavioral deficits
in transgenic mice (Bien-Ly et al., 2011). In vitro and in vivo
studies suggest that the low-density lipoprotein (LDL) receptor,
the LDL receptor-related protein-1 (LRP1), and the very-low-
density lipoprotein (VLDL) receptor are all involved in apoE-
mediated Ab clearance from brain (Bu, 2009; Deane et al.,
2008; Kim et al., 2009).
While apoE4 clearly increases Ab accumulation and amyloid
plaque formation in both humans and transgenic mouse models(Figure 3A), it is still uncertain if this process actually contributes
to cognitive deficits in AD. As indicated above, plaque loads
determined histopathologically or radiologically do not correlate
well with cognitive impairments in humans (Giannakopoulos
et al., 2003). Furthermore, in the oldest old (>90 years of age),
the presence of apoE2 is associated with a reduced risk of
dementia but an increased amyloid burden, relative to apoE3
(Berlau et al., 2009).
Ab-Independent Roles of apoE4 in AD Pathogenesis. Several
transgenic or gene-targeted mouse lines expressing human
apoE3 or apoE4 have been established, without coexpression
of mutant hAPP. Transgenic mice expressing apoE4 in neurons
on a murine Apoe knockout background show age- and female
gender-dependent spatial learning and memory deficits that are
not observed in neuron-specific apoE3 mice (Raber et al., 1998;
Raber et al., 2000). Morphological studies demonstrated that
neuronal apoE3, but not apoE4, prevents the age-dependent
neurodegeneration seen in apoE-null mice as well as excito-
toxin-induced neurodegeneration (Buttini et al., 2010; Buttini
et al., 1999). ApoE4 also impairs synaptogenesis and decreases
dendritic spine density in vivo in apoE transgenic and gene-
targetedmice and in vitro in primary neuronal cultures (Brodbeck
et al., 2011; Dumanis et al., 2009). In addition, neural stem cells in
adult mice express apoE and apoE4 impairs adult hippocampal
neurogenesis (Li et al., 2009), which might also contribute to
apoE4-associated learning and memory deficits. Since there is
no Ab accumulation in any of these apoE4 mouse models, these
data strongly suggest an Ab-independent role of apoE4 in
causing neuronal and behavioral deficits in vivo. In support of
this notion, effects of apoE4 on cortical thickness, brain activity
and mitochondrial function have been detected in children or
college students (Filippini et al., 2009; Shaw et al., 2007), i.e.,
well before significant Ab accumulation appears to occur in
human brains (Braak et al., 2011).
It has been hypothesized that, in response to brain stresses or
injuries, neuronal apoE expression is induced for purposes of
repair or remodeling. Notably, this process also causes proteo-
lytic cleavage of apoE4, resulting in fragments that lead to
neuronal dysfunction and degeneration (Figures 2B and 2C)
(Huang, 2006, 2010; Mahley et al., 2006). Indeed, neuronal
apoE4 is more susceptible than neuronal apoE3 to proteolytic
cleavage, resulting in the generation of C-terminally truncated
neurotoxic fragments (Brecht et al., 2004). ApoE fragments are
present at much higher levels in the brains of AD patients than
in those of age- and sex-matched nondemented controls (Harris
et al., 2003; Jones et al., 2011). Transgenic mice expressing the
C-terminally truncated fragment of apoE have neurodegenera-
tion in the hippocampus and show spatial learning and memory
deficits (Andrews-Zwilling et al., 2010; Harris et al., 2003).
C-terminally truncated apoE4 increases tau phosphorylation
and the formation of intracellular NFT-like inclusions in cultured
neuronal cells and in transgenic mice (Figures 3B and 3C)
(Huang, 2006, 2010; Mahley et al., 2006). Thus, neurotoxicity
induced by the apoE4 fragments might be related to the forma-
tion of neurotoxic tau species. In line with this hypothesis,
removing endogenous tau prevents neuronal and behavioral
deficits in apoE4 fragment-transgenic mice (Andrews-Zwilling
et al., 2010). ApoE4 fragments also target neuronalmitochondria,Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1209
Figure 4. Roles of Tau in Different Tauopathies
Mutations in MAPT, the gene that encodes tau, result in the production of
mutant tau and cause certain forms of frontotemporal dementia (FTD) but
never AD. In AD, Ab and apoE4 act upstream of wild-type tau and their adverse
effects depend, at least partly, on tau whose structure or function may be
altered by abnormal posttranslational modification, mislocalization or other
variables. Indeed, tau reduction prevents Ab and apoE4 fragments from
causing neuronal and behavioral deficits in mouse models. The exact mech-
anisms by which tau contributes to neuronal dysfunction and degeneration in
AD, FTD and other tauopathies remain to be determined.leading to mitochondrial dysfunction and neurotoxicity (Fig-
ure 3B and 3C) (Chang et al., 2005; Chen et al., 2012). Notably,
mitochondrial dysfunction in AD is greater in apoE4 than in
apoE3 carriers (Gibson et al., 2000). ApoE4 is also associated
with decreased cerebral glucosemetabolism in both AD patients
and nondemented subjects (Small et al., 2000), which likely
reflects apoE4-dependent mitochondrial dysfunctions.
ApoE4-Induced Impairment of GABAergic Interneurons.
ApoE4 knockin mice show an age-dependent decrease in hilar
GABAergic interneurons, which correlates with the extent of
apoE4-induced impairments of adult hippocampal neurogenesis
and with learning and memory deficits (Andrews-Zwilling et al.,
2010; Li et al., 2009). In transgenic mice expressing neurotoxic
apoE4 fragments, the loss of hilar interneurons is more
pronounced and also correlates with learning and memory defi-
cits (Andrews-Zwilling et al., 2010). These adverse effects are
prevented by tau removal (Andrews-Zwilling et al., 2010). Mice
treated with the GABAA receptor potentiator pentobarbital
exhibit normal neurogenesis and learning and memory
(Andrews-Zwilling et al., 2010; Li et al., 2009). These findings
strongly suggest that apoE4 causes age- and tau-dependent
impairment of hilar GABAergic interneurons, leading to
decreased neurogenesis in the hippocampus and to learning
and memory deficits (Figure 3B).
Dysfunction of the GABAergic system may also contribute to
cognitive impairment in humans. AD patients have decreased
GABA and somatostatin levels in the brain and CSF, and these
alterations are more severe in apoE4 carriers (Grouselle et al.,
1998). ApoE4 is associated with increased brain activity at rest
and in response to memory tasks (Dennis et al., 2010; Filippini
et al., 2009), possibly reflecting impaired GABAergic inhibitory
control. A single-nucleotide polymorphism in the somatostatin1210 Cell 148, March 16, 2012 ª2012 Elsevier Inc.gene increases the risk for AD in carriers of apoE4 but not of
apoE3 (Vepsa¨la¨inen et al., 2007). Furthermore, GABA levels in
human CSF decrease with aging (Bareggi et al., 1982)—the
strongest risk factor for AD. We hypothesize that apoE4 contrib-
utes to AD pathogenesis, at least partially, by causing age-
dependent impairments of GABAergic interneurons (Figure 3B).
Tau and Other Copathogens
AD is clearly a polyproteinopathy in which multiple proteins
assume potentially pathogenic conformations and accumulate
separately or together in the brain. Based on the pathological
definition of the disease, AD is associated not only with the
abnormal accumulation of amyloid plaques, but also with that
of NFTs. NFTs form intracellularly and are made up primarily of
aggregated tau bearing abnormal posttranslational modifica-
tions, including increased phosphorylation and acetylation
(Cohen et al., 2011; Iqbal et al., 2010; Min et al., 2010). Several
recent findings have challenged the traditional views that tau
functions primarily to stabilize microtubules and that its aggre-
gation in AD causes deficits through a loss-of-function mecha-
nism (Morris et al., 2011). Studies in cell culture and genetically
modified mouse models suggest that tau may normally facilitate
or enhance excitatory neurotransmission by regulating the distri-
bution of synaptic activity-related signaling molecules (Morris
et al., 2011). However, when it is abnormally modified and
assumes pathogenic conformations, tau becomes enriched in
dendritic spines where it can interfere with neurotransmission
(Hoover et al., 2010). Ab oligomers promote this postsynaptic
enrichment of tau through a process that involves members of
the microtubule affinity-regulating kinase (MARK) family (Yu
et al., 2012; Zempel et al., 2010).
Interestingly, tau reduction prevents Ab from causing neuronal
deficits in cell culture and hAPP transgenic mice (Morris et al.,
2011). Thus, while Ab acts upstream of tau, its adverse effects
depend in good part on tau (Figure 4). These conclusions are
consistent with genetic studies: mutations in APP or presenilins
that cause Ab accumulation in the brain cause AD with amyloid
plaques and NFTs (Bertram et al., 2010), whereas tau mutations
cause NFTs but neither amyloid plaques nor AD (Figure 4). The
latter mutations cause frontotemporal lobar degeneration
instead (Ballatore et al., 2007). ApoE4 and its fragments increase
tau phosphorylation and accumulation in the neuronal soma and
dendrites (Andrews-Zwilling et al., 2010; Brecht et al., 2004;
Harris et al., 2003). Moreover, tau reduction also prevents
apoE4-dependent neuronal deficits in vitro and in vivo (An-
drews-Zwilling et al., 2010), pinpointing tau as a key mediator
or enabler of both Ab- and apoE4-dependent pathogenesis
(Figure 4). As reviewed above, apoE isoforms modulate both
Ab deposition as well as plaque-independent synaptic and
cognitive deficits in hAPP mice, with apoE4 enhancing and
apoE3 counteracting the abnormalities, further highlighting the
copathogenic relationships among Ab, tau and apoE4.
A large proportion of AD cases also have abnormal accumu-
lations of the presynaptic protein a-synuclein and of the RNA-
binding protein TDP-43 in the brain (Higashi et al., 2007). As
with tau, mutant forms of these proteins do not cause AD, but
other neurodegenerative disorders. Ab enhances the misfolding
and accumulation of a-synuclein in vitro and in vivo, and studies
in doubly transgenic mice suggest that these molecules can
synergize to more severely impair neuronal functions (Masliah
et al., 2001). Likewise, apoE4 fragments may enhance the
accumulation of TDP-43 in neurons of FTD patients (Vossel
et al., 2012).
Potential Common Mechanisms
Like Ab, tau and a-synuclein can exist in different assembly
states, and several lines of evidence suggest that smaller aggre-
gates such as soluble oligomers are more pathogenic than
larger, insoluble, highly ordered, fibrillar aggregates (Morris
et al., 2011; Winner et al., 2011). An interesting question that
remains unresolved is whether the in vivo pathogenicity of these
and other proteins associated with neurodegenerative disorders
depends on specific conformations (e.g., b-pleated sheet
structures) and whether the proteins require self-aggregation
or binding to other proteins to assume these conformational
states. At least for tau and a-synuclein, both of which are intrin-
sically disordered proteins, it is conceivable that evenmonomers
could assume pathogenic conformations under circumstances
that promote protein misfolding. Experimental evidence for
such a scenario has recently been obtained for huntingtin
bearing disease-associated polyglutamine repeat expansions
(Miller et al., 2011).
Whether the various pathogenic protein conformations or
assemblies impair neuronal functions through common,
distinct, or partly overlapping mechanisms also remains to be
determined. The copathogenic interactions that have been
identified among tau, apoE4, Ab, and a-synuclein (see above)
suggest that there are probably downstream mechanisms on
which the effects of these proteins converge. Abnormalities in
the activity or distribution of neurotransmitter receptors and
downstream signaling cascades, excitotoxicity, and dysregu-
lation of intracellular calcium homeostasis, alterations in the
intracellular transport of critical cargoes, mitochondrial impair-
ments, epigenetic dysregulation, and engagement of patho-
genic glial loops are among the possible convergence points.
It is unfortunate that the identification of such diverse possibili-
ties is often misinterpreted as controversy or lack of under-
standing. After all, even normal proteins often have multiple
functions and different activities under different circumstances,
cytokines such as TGF-b being a good example. There is no
reason why the activity of pathogenic proteins should be less
complex. Therefore, the various mechanisms listed above are
clearly not mutually exclusive. In fact, some of them may be
related, e.g., intracellular transport deficits and mitochondrial
dysfunction.
In addition, abnormal folding and accumulation of multiple
proteins could nonspecifically stress and ultimately overload
the cellular protein handling machinery. Much evidence sug-
gests that autophagy is the main mechanism by which cells
clear abnormal protein aggregates (Harris and Rubinsztein,
2011). In the most common form of autosomal dominant AD,
mutant PS1 may disrupt autophagy directly by impeding lyso-
somal proteolysis, whereas in other forms of AD autophagy
impairments may involve different genetic or environmental
factors (Nixon and Yang, 2011). Attempts to restore normal
lysosomal proteolysis and autophagy in mouse models of AD
have yielded promising therapeutic effects, lowering Ab levels
and improving neuronal function as well as cognitive perfor-mance (Nixon and Yang, 2011; Pickford et al., 2008; Yang
et al., 2011a).
Another interesting aspect of Ab, tau, a-synuclein and other
proteins associated with neurodegenerative disorders is their
ability to perpetuate pathology through cell-to-cell spread
and seeding of abnormal protein aggregation in experimental
models. These properties have been compared to those
of prions, different forms of which cause Jacob-Creutzfeldt
disease, scrapie, and mad-cow disease (Braak and Del Tredici,
2011; Jucker and Walker, 2011). However, prions differ funda-
mentally from the other proteins in that they cause diseases
that are communicable, which AD and most other neurodegen-
erative disorders are not.
It is well established that neurodegenerative disorders are
strongly linked to aging. However, it remains uncertain whether
this link is specifically caused by aging-related processes or
simply reflects the time required for the relevant pathogenic
processes to unfold. Genetic changes that accelerate the
accumulation of pathogenic proteins in the brain can clearly
override the aging ‘‘requirement’’ and cause AD or other neuro-
degenerative conditions in middle-aged or even young people.
Nonetheless, diverse lines of experimental evidence support
the notion that AD and other neurodegenerative conditions
may be enabled by specific aging-related factors, such as
gradual failure of neuroprotective or protein clearance mecha-
nisms and the emergence of comorbidities (Herrup, 2010;
Mawuenyega et al., 2010; Villeda et al., 2011). Inflammation
may be a key component of unhealthy aging (Sastre et al., 2011).
Last but not least, both Ab and apoE4 can contribute to
network and cognitive dysfunction by impairing specific popu-
lations of inhibitory interneurons that normally regulate the
activity of excitatory principal cells (Figures 2B, 2C, and 3B).
Fast-spiking parvalbumin-positive GABAergic interneurons in
the parietal cortex of hAPP mice have reduced levels of
voltage-gated sodium channel (VGSC) subunits (Figures 2B
and 2C), and similar alterations are present in patients with AD
(Verret et al., 2012). Increasing the level of these sodium channel
subunits in the transgenic mice improves gamma oscillations,
network activity and cognitive functions. Exploratory activity
also increases gamma intensity and reduces network hypersyn-
chrony in some of the mice. ApoE4 and its fragments cause
age- and tau-dependent impairments of somatostatin-positive
GABAergic interneurons in the hilus of the dentate gyrus, leading
to learning andmemory deficits (Figure 3B). Stimulation of GABA
signaling reverses these deficits (Andrews-Zwilling et al., 2010).
Thus, improving the function of interneurons may be an inter-
esting new entry point for therapeutic interventions in AD.
Preclinical and Clinical Trials
Acetylcholine Esterase Inhibitors and Memantine
Drugs that are currently approved by the FDA for the treatment of
AD inhibit acetylcholine esterase to increase the levels of the
neurotransmitter acetylcholine, which is depleted in AD brains,
or antagonize NMDA-type glutamate receptors to prevent
aberrant neuronal stimulation (Cummings, 2004). The impact of
these drugs on disease manifestations is modest and transient,
although observational studies suggest that combination treat-
ment may increase the time before patients require nursingCell 148, March 16, 2012 ª2012 Elsevier Inc. 1211
home care (Lopez et al., 2009). There is no convincing evidence,
though, that these agents can prevent, halt, or reverse the
disease.
Targeting Ab
Based on groundbreaking discoveries made during the last two
decades, several therapeutics have been developed to decrease
the production or enhance the clearance of Ab. Drugs in the
former category are designed to inhibit b- or g-secretase, the
enzymes that release Ab from its precursor (Citron, 2010; De
Strooper et al., 2010; Golde et al., 2011). Although the identity
of these enzymes has been known for a long time, it has been
difficult to develop drugs that penetrate the BBB and specifically
inhibit the cleavage of APP without affecting the cleavage of
alternative substrates such as Notch and voltage-gated sodium
channel subunits (Citron, 2010; De Strooper et al., 2010; Golde
et al., 2011). A phase III clinical trial of a g-secretase inhibitor
was recently stopped because of side effects that included
worsening of cognitive impairments (Schor, 2011). Another
category of drugs modulates g-secretase cleavage of APP,
decreasing the production of Ab42/43 in favor of shorter Ab
species that may be less toxic than the longer species (Golde
et al., 2011; Karran et al., 2011). However, it has not yet been
rigorously excluded that the shorter Ab species also contribute
to neuronal dysfunction in vivo, a possibility that could limit the
efficacy and safety of g-secretase modulators. The g-secretase
modulator tarenflurbil was ineffective in a phase III trial (Green
et al., 2009). Ongoing trials will assess whether more selective,
Notch-sparing g-secretase inhibitors or b-secretase (BACE1)
inhibitors are more efficacious and safe.
Efforts to lower Ab levels through enhanced clearance
emerged from the demonstration that active immunization
against Ab cleared amyloid plaques in hAPP transgenic mice
(Schenk et al., 1999). An active immunization trial in humans
had to be stopped because of immunopathological side effects
(Gilman et al., 2005). Passive immunization by repeated infusions
of humanized monoclonal anti-Ab antibodies in a phase II trial
was better tolerated, although amyloid-related imaging abnor-
malities, including vasogenic edema and microhemorrhages,
were noted on MRI scans in a proportion of patients (Salloway
et al., 2009; Sperling et al., 2011b). This trial was subsequently
extended to a phase III trial with decreased doses of the antibody
in apoE4 carriers, who were particularly susceptible to the above
complications, and results are expected to become available
later this year. Additional investigational anti-Ab therapeutics
include drugs that aim to prevent the formation of pathogenic
Ab assemblies, such as scyllo-inositol, which showed no
efficacy in a phase II trial (Salloway et al., 2011), and PBT2, which
showed preliminary promise in a small phase IIa trial (Lannfelt
et al., 2008).
An alternative or complementary approach to those described
above may be to make the brain more resistant to whatever Ab
cannot be removed effectively and safely (Figure 2A, 2C, and
2D). Several experimental strategies have been identified that
prevent or reverse hAPP/Ab-dependent neuronal and cognitive
impairments in transgenic mice, including reductions of tau
(Morris et al., 2011), group IVA phospholipase A2 (Sanchez-Mejia
et al., 2008), cyclophilin D (Du et al., 2008), or Fyn (Chin et al.,
2004); reversal of EphB2 or Nav1.1 depletions (Cisse´ et al.,1212 Cell 148, March 16, 2012 ª2012 Elsevier Inc.2011; Verret et al., 2012); and replacement of apoE4 with
apoE3 (Buttini et al., 2002; Raber et al., 2000). More research
is needed to further assess the therapeutic potential and safety
of these strategies.
Targeting Tau
Although far fewer drug trials have focused on tau, interest in
tau-related therapeutics has been growing steadily in recent
years, in part because of the difficulties encountered with anti-
Ab strategies (Brunden et al., 2009; Golde et al., 2011; Morris
et al., 2011). In human AD patients, the phenothiazine methylene
blue showed some promise for slowing disease progression
in a phase II clinical trial conducted for one year (Gura, 2008).
Methylene blue was originally thought to inhibit tau-tau inter-
actions, but it may also reduce soluble tau through other mech-
anisms as it is known to have many targets (Schirmer et al.,
2011). Phase III trials with a newer formulation of methylene
blue (LMTX) are planned.
Because it is uncertain which tau assembly or conformation
is responsible for tau-dependent neuronal dysfunction and
degeneration, it is equally uncertain whether the abundance of
this structure is reduced by any of the available tau aggregation
blockers. In fact, some tau aggregation inhibitors enhance the
formation of potentially toxic tau oligomers (Taniguchi et al.,
2005). This scenario is reminiscent of the current state of anti-Ab
treatments, where it is also unclear whether any of the anti-Ab
strategies that have undergone or are currently in clinical trials
significantly reduce the abundance of the most pathogenic
soluble Ab assemblies in human brain tissues, whatever those
may be (Benilova et al., 2012).
Because several lines of evidence suggest that abnormal
phosphorylation contributes to the pathogenicity of tau (Hoover
et al., 2010; Morris et al., 2011; Zempel et al., 2010), tau kinases
continue to be pursued as potential drug targets for AD,
including GSK-3b, CDK5, MARK, and MAPK. However, all of
these kinases have numerous other substrates besides tau,
raising concerns about the safety of respective inhibitors, and
so far no tau kinase inhibitor appears to have advanced to
a late-phase clinical trial for AD.
A potential alternative to modulating tau phosphorylation is
reducing overall tau levels. In mice, 50% reduction of endoge-
nous tau is well tolerated, increases resistance to chemically
induced seizures, and markedly reduces Ab- and apoE4
fragment-induced neuronal and cognitive impairments in vivo
(Morris et al., 2011). Assuming ongoing experiments confirm
that reduction of overall tau levels is efficacious and safe
also when initiated in adult and old animals with AD-related
pathologies, it may be worthwhile to reduce tau levels by target-
ing tau itself or molecules that regulate its expression or clear-
ance. Some relevant molecules have already been identified.
For example, dihydropyridines lower tau levels in cell cultures
(Evans et al., 2011).
Tau is thought to be degraded via the ubiquitin-proteasome
and lysosomal pathways. The ubiquitin ligase for tau has been
identified as the C terminus of HSP70-interacting protein
(CHIP). Reduction of CHIP levels increased the accumulation
of tau aggregates in human tau transgenic mice, and CHIP levels
are reduced in AD brains (Sahara et al., 2005). Furthermore, as its
name suggests, CHIP works in combination with heat shock
proteins to regulate tau degradation (Dickey et al., 2007); levels
of heat-shock protein 90 (Hsp90) correlate inversely with the
levels of soluble tau and tau oligomers (Sahara et al., 2007).
In AD brains, tau is hyperacetylated, which increases its
half-life (Min et al., 2010), alters its microtubule binding, and
enhances aggregation (Cohen et al., 2011). Because both acet-
ylation and ubiquitination target lysine residues, acetylation of
tau by the acetyl transferase p300 inhibits ubiquitination and
stabilizes tau (Min et al., 2010). In addition, acetylation of the 6
amino acid motif VQIINK (PHF6*) inhibits the binding of tau to
microtubules and enhances tau aggregation (Cohen et al.,
2011). This motif is critical for the formation of tau oligomers
and filaments (Morris et al., 2011). Thus, the combination of
inhibiting tau acetylation and enhancing proteasome function
might synergize to lower the level of pathogenic tau species.
Tau degradation can also be enhanced by immune-mediated
mechanisms. Active immunization targeting phosphorylated tau
reduced filamentous tau inclusions and neuronal dysfunction in
tau transgenicmice (Asuni et al., 2007). Themechanism bywhich
intracellular proteins, including tau and a-synuclein, are cleared
by immunization is not known but may involve lysosomal degra-
dation (Masliah et al., 2005; Sigurdsson, 2009). Once antibodies
enter the brain, they could be taken up by receptor-mediated
endocytosis and activate autophagy (Sigurdsson, 2009) or
interact with tau or a-synuclein in the extracellular milieu.
Microtubule disruption has been observed in several models
of AD and FTLD, including tau transgenic mice and wild-type
neuronal cultures exposed to Ab oligomers (Brunden et al.,
2010; Morris et al., 2011). Microtubule stabilizers have shown
promise in preclinical and clinical trials for AD. For example,
paclitaxel prevented Ab-induced toxicity in cell culture (Zempel
et al., 2010), as well as axonal transport deficits and motor
impairments in tau transgenic mice (Zhang et al., 2005). Epothi-
lone D, which has better BBB permeability, improves microtu-
bule density and cognition in tau transgenic mice (Brunden
et al., 2010). The peptide NAP stabilizes microtubules and
reduces tau hyperphosphorylation (Vulih-Shultzman et al.,
2007), suggesting that microtubule-stabilizing compounds can
have more than one mechanism of action. NAP can be adminis-
tered intranasally and showed some promise in a phase II clinical
trial (Gozes et al., 2009).
Targeting ApoE4
Targeting Ab-Dependent Effects of apoE4. Approaches target-
ing Ab-dependent effects of apoE4 have focused on modifying
apoE levels or its Ab binding property to enhance Ab clearance
or decrease Ab deposition (Kim et al., 2009). Studies in humans
and transgenic mice show that brain Ab levels and amyloid pla-
que formation are apoE isoform dependent (apoE4 > apoE3 >
apoE2) (Castellano et al., 2011; Kim et al., 2009). Brain apoE
levels are also isoform dependent, but in the opposite direction
(apoE4 < apoE3 < apoE2) (Bales et al., 2009; Riddell et al.,
2008). The apoE4 allele was deemed hypomorphic because
apoE4 levels in plasma and brain tend to be lower than those
of apoE3, which might reduce apoE4’s capacity for Ab clear-
ance. Based on this hypothesis, it has been proposed to
increase apoE expression in brain in the hope that this would
stimulate Ab clearance and reduce Ab levels (Bales et al.,
2009; Riddell et al., 2008). However, recent studies directlytested this hypothesis in mice and reported that increasing
expression levels of apoE3 or apoE4 in mutant hAPP or hAPP/
PS1 transgenic mice actually increased amyloid deposition in
their brains (Bien-Ly et al., 2012; Kim et al., 2011). Thus, in
contrast to the original hypothesis, this finding suggests that
reducing, rather than increasing, apoE expression could be
a promising approach to lowering brain Ab levels and decreasing
plaque loads. Studies are needed to further test this alternative
hypothesis.
Other efforts to attenuate apoE4’s ability to promote Ab
deposition have focused on blocking the interaction between
apoE and Ab (Sadowski et al., 2006; Yang et al., 2011b). For
example, the BBB-permeable synthetic peptide Ab12-28P, which
is homologous to the binding site of apoE on Ab but bears a
strategic single amino acid substitution, and reduces Ab toxicity
in cell culture and amyloid deposition in hAPP transgenic
mice (Sadowski et al., 2006; Yang et al., 2011b). However,
these findings were obtained in mice that express murine
rather than human apoE. The effect of murine apoE on Ab
metabolism clearly differs from that of human apoE in that
mouse apoE promotes Ab deposition, whereas human apoE
promotes Ab clearance (Bien-Ly et al., 2011; Holtzman et al.,
1999). Therefore, it is conceivable that blocking the interaction
between Ab and human apoE at young ages might promote
amyloid deposition.
Targeting Ab-Independent Effects of apoE4. Several
approaches have been proposed to target the Ab-independent
effects of apoE4 (Figure 3C). One approach is to identify small-
molecule structure correctors capable of disrupting apoE4
domain interaction (Huang, 2006, 2010; Mahley et al., 2006).
Since domain interaction is responsible for multiple detrimental
effects of apoE4 (Brodbeck et al., 2011; Chen et al., 2012;
Huang, 2006, 2010; Mahley et al., 2006), blocking it should
abolish or attenuate those detrimental effects. Toward this
goal, small molecules with high potency have been identified
by structure-assisted in silico pharmacophore modeling, rational
drug design, and high-throughput screening. These compounds
abolish apoE4 domain interaction in neuronal cultures, improve
apoE4 intracellular trafficking, and prevent the detrimental
effects of apoE4 on neurite outgrowth, mitchondrial motility
and function, and Ab production in cultured neuronal cells
(Brodbeck et al., 2011; Chen et al., 2012; Ye et al., 2005). Another
approach is to identify the protease that cleaves apoE4 and
generates neurotoxic fragments and to develop specific
protease inhibitors (Huang, 2006, 2010; Mahley et al., 2006).
Alternatively, humanized monoclonal antibodies specific for the
neurotoxic apoE fragments could be used to clear the fragments
or to block their detrimental actions. An additional approach is
to protect mitochondria and the cytoskeleton from attack by
the toxic apoE fragments (Huang, 2006; Mahley et al., 2006).
Reduction of apoE4 expression in neurons should also reduce
the level of toxic apoE fragments and their downstream effects
(Huang, 2006). Finally, synthetic apoE mimetic peptides have
been shown to be neuroprotective in mouse models of acute
brain injury and in a Drosophila model overexpressing hAPP
(Laskowitz et al., 2007; Sarantseva et al., 2009). Although these
approaches targeting the Ab-independent effects of apoE4 are
promising, they are all at an early stage of development andCell 148, March 16, 2012 ª2012 Elsevier Inc. 1213
need to be evaluated in animal models and, ultimately, in clinical
trials to further assess their therapeutic potential.
Other Therapeutic Approaches
Because there is plenty of evidence for oxidative damage,
inflammation and mitochondrial impairments in AD (Bezproz-
vanny, 2010; Galimberti and Scarpini, 2011; Perry et al., 2010),
several attempts have been made to slow disease progression
with antioxidants (Lee et al., 2010a), anti-inflammatory drugs
(Cole and Frautschy, 2010), or putative mitochondrial protectors
(Bezprozvanny, 2010). However, based on our interpretation of
the literature, no effective treatment has emerged from these
efforts so far. Hormone therapy has been similarly disappointing
(Shumaker et al., 2003). A number of interesting experimental
strategies are currently under investigation that target synaptic
or network dysfunction (Koh et al., 2010; Palop and Mucke,
2010; Verret et al., 2012), modulators of aging (Cohen et al.,
2009; Gan andMucke, 2008), or autophagy (Harris and Rubinsz-
tein, 2011). Time will tell whether these or other new strategies
can be developed into more effective therapeutics for AD.
Lessons Learned and New Developments
The Basics
For many of the clinical trials that have been carried out on AD
patients, there is no clear evidence that the treatment actually
had the desired effect on the intended target within AD-
vulnerable brain regions. Some of the drugs that were tested in
advanced clinical trials may not even effectively penetrate the
BBB. Furthermore, the extent of the required target modulation
is often uncertain, simply because the pertinent pathobiology
has not yet been worked out in adequate detail. For example,
how much of a secretase inhibitor or an anti-Ab antibody does
it take to lower functionally relevant Ab assemblies in the
hippocampus and entorhinal cortex to a level where they can
no longer impair synaptic functions? And what happens to
alternate substrates or potentially cross-reactive epitopes at
these doses? Do apoE isoforms differentially affect the actions
or efficacies of the tested drugs? What exactly is it that anti-
inflammatory drugs should accomplish in the brain to counteract
AD and what would be a good outcome measure to ensure this
goal was achieved? If enrichment of tau in dendritic spines is
critical for its pathogenic effects, do tau-related drugs actually
modulate tau in this subcellular compartment? There are myriad
questions like these that have not yet been answered and that
will likely have to be addressed to develop and rigorously
assess new AD therapies. Indeed, there is a dire need for
scientists to build a more solid knowledge base for AD and
other neurodegenerative disorders to enable truly rational
design and evaluation of new therapeutics.
Too Little, Too Late
It may be possible to learn valuable lessons from other chronic
diseases that become manifest primarily in older people, in
particular cardiovascular disease. For example, effective
management of hypertension often requires the combination of
drugs that have different modes of action, such as diuretics,
b blockers and ACE inhibitors. Might cognitive impairments in
AD require a similar combination of different drugs, e.g., aimed
at Ab, tau, and apoE4? If multiple risk factors are present at a
young age, the prevention of strokes, heart attacks, and hyper-1214 Cell 148, March 16, 2012 ª2012 Elsevier Inc.tensive cardiomyopathy often requires initiation of a multi-
pronged approach many years, even decades, before these
complications typically occur (stop smoking, lose weight, lower
blood pressure and cholesterol, etc.). However, once these
complications have occurred, they respond poorly or not at all
to such interventions.
AD researchers increasingly view the cognitive failure that
becomes evident at the clinical onset of AD as the late-stage
complication of a process that has progressed silently for
many years (Golde et al., 2011). They further suspect that risk
factors for AD might be detectable decades before the first
impairments are identified on cognitive testing. This line of
thinking and new data supporting it have recently led to
a substantial revision of the diagnostic research criteria for AD
(Jack et al., 2011). The new criteria assume that clinical manifes-
tations of AD are preceded by a long prodromal phase and
place much greater emphasis on biomarkers such as MRI
scans, PIB scans, and measurements of Ab and tau in the cere-
brospinal fluid. Promising efforts are underway to identify more
sensitive and specific biomarkers that might allow for the earlier
identification of people at risk for developing the disease and
for evaluating the efficacy of new treatments in clinical trials
(Hampel et al., 2010; Reddy et al., 2011). However, at this point
we do not yet have the AD equivalents of blood pressure or
cholesterol measurements, which have been so helpful in pre-
venting cardiovascular disease.
To our knowledge, all previous and ongoing clinical trials for
AD were initiated in symptomatic patients, whose disease may
have already progressed to a point where treatments with
preventive potential have become ineffective. The cohorts of
patients that are being assembled in the dominantly inherited
Alzheimer’s network (DIAN) (Bateman et al., 2011) and the
Alzheimer’s Prevention Initiative (API) (Reiman et al., 2011)
should change this situation, as they should allow for the design
of carefully timed preventive trials in carriers of mutations that
predictably cause early-onset AD within relatively narrow age
ranges.
The increasing emphasis on prevention raises the intriguing
question of whether it is at all possible to halt or reverse AD
once cognitive impairments have emerged. While many AD
researchers are increasingly skeptical about this possibility, the
authors have a more optimistic perspective, primarily because
of the extraordinary plasticity of the nervous system, which far
exceeds that of other organs. We think that a cocktail of drugs
that block not just one, butmost root causes of the disease could
have beneficial effects even in AD patients with cognitive defi-
cits, especially if combined with drugs that optimize network
activity and promote neural plasticity and repair. Combination
treatment has certainly made a world of difference in the
treatment of other challenging conditions such as cancer and
AIDS. Notably, these biomedical success stories include major
improvements in cognitive functions in people with well-estab-
lished HIV-associated dementia following combination antiretro-
viral therapy (Cysique and Brew, 2009).
Safety First?
However, most physicians and relatives taking care of elderly
people have learned painfully that this fragile patient population
is prone to treatment failures and side effects. Reasons include
Figure 5. Impact of Patient Heterogeneity
and Modifier Genes on Drug Trials
Hypothetical data clouds with dots representing
memory measures obtained in individual human
subjects.
(A) Without better preselection of patients,
potentially effective new drugs may show no effi-
cacy in clinical trials because of the heterogeneity
of the patient population tested.
(B and C) Stratification of patient populations
based on measurements of biomarkers and iden-
tification of specific genes could help match up
subpopulations with the most suitable drug and
significantly increase the chances of identifying
better treatments for AD and related disorders.aging-related changes in metabolism and the accrual of comor-
bidities requiring multiple drugs that can interact unfavorably
with new ones added to the mix. Evaluating the safety and effi-
cacy of combination treatments on this complex background is
a daunting task. The concept of early preventive interventions
(see above) further raises the safety bar for AD drugs, as it
implies treating large numbers of otherwise healthy people for
prolonged periods of time. But how much risk is unacceptable
if losing one’s mind is the alternative? Because the answer to
this question varies widely among different people, regulatory
agencies need to strike the right balance between protecting
the public from harm and unduly restricting progress or freedom
of choice. Advances in systems biology, the emergence of
personalized medicine, and use of cells differentiated from
patient-specific induced pluripotent stem cells (iPSCs) for
preclinical drug tests (Bousquet et al., 2011; Brennand et al.,
2011; Israel et al., 2012) will likely facilitate this challenging
task in the future, as these promising developments could
improve our ability to preselect those subjects for clinical trials
that have the highest chance of benefiting from specific treat-
ments and the least chance of suffering ill effects.
Heterogeneity of Patient Populations and Modifier
Genes
As described above, AD is a complex neurodegenerative
disorder that is probably caused by interactions among multiple
genetic, epigenetic, and environmental factors and pathways.
This multifactoriality contributes to the heterogeneity of patient
populations and makes it difficult to test drugs in clinical trials
without pre-selecting appropriate patient groups and matching
them up with the most suitable drugs (Figure 5). For example,
are autosomal dominant early-onset AD and sporadic late-onset
AD the same disease? Does AD presenting with amnestic versus
executive deficits have the same or distinct etiologies? Firm
answers to these questions are currently lacking but could
have an important impact on the efficacy of drugs related to
Ab, apoE4, or other pathogens. The impact of apoE4 on AD
risk is also affected by ethnicity (Farrer et al., 1997), intro-
ducing another layer of complexity. Therefore, beyond the iden-
tification of reliable early biomarkers for AD overall (see above),
there is a need to define early biomarkers for potential AD
subtypes.
Another important objective is to determine why some indi-
viduals are able to ‘‘escape’’ from the functional impact of
the disease even when they have strong risk factors such asapoE4 or extensive AD pathology. Among the first factors to
emerge in this quest is reelin, an extracellular matrix glycopro-
tein. It promotes synaptic plasticity, is depleted in vulnerable
neuronal populations in AD patients and in hAPP mice, and
can counteract Ab-induced synaptic dysfunction (Chin et al.,
2007; Durakoglugil et al., 2009). A recent GWAS identified vari-
ants of the reelin-encoding RELN gene that are associated
with normal cognitive function in elderly people with substantial
AD-like pathology (Kramer et al., 2011). Ongoing studies
using whole genome sequencing and other systems biology
approaches will probably reveal additional factors that prevent
AD in some people against all odds and that, if effectively har-
nessed, may be able to prevent the conditions also in others.
Values and Limitations of Experimental Models
Evolutionary pressures do not allow for much slack and have
preserved many processes and mechanisms across diverse
species. However, there also are some striking differences
among species that must be born in mind when trying to extrap-
olate from one to the other (Miller et al., 2010). Are there good
experimental models for AD? The answer to this question
depends entirely on what one expects from models. If one looks
for models that simulate all aspects of the human condition
and allow for reliable predictions of drug efficacy and safety in
clinical trials, most would probably arrive at the conclusion that
no good AD models exist. In contrast, if one looks for models
that can help dissect the complexity of the human condition
and provide useful information on the pathogenic impact and
underlying mechanisms of specific factors, there are plenty.
Although many different types of models can be informative,
including the most reductionist, it is critical to confirm findings
across models and, ultimately, in the human condition. It is
equally important to swiftly adjust working hypotheses based
on new information gained in this process. For example, Ab
promotes the aggregation of a-synuclein not only in cell-free
conditions, but also in neuronal cell cultures and transgenic
mouse models (Masliah et al., 2001). In contrast, although tau
effectively stabilizes microtubules in cell-free conditions, it
does not appear to be required for this purpose in cell culture
or adult mouse brains, calling into question the dogma that the
main function of tau is to stabilize microtubules (Morris et al.,
2011).
Advances in iPSC technologies and related approaches now
allow for the generation of human brain cells from patient-
derived fibroblasts or blood cells and have already allowed forCell 148, March 16, 2012 ª2012 Elsevier Inc. 1215
the identification of phenotypes with potential relevance to
schizophrenia (Brennand et al., 2011) and AD (Israel et al.,
2012). These exciting developments have renewed interest in
cell culture models. Even conventional cell culture models
have proved very useful in AD research. For example, they
have taught us much about APP processing, Ab production,
and differential effects of apoE isoforms, and many of the find-
ings obtained in thesemodels have held upwell in animal models
and humans (Bertram et al., 2010; Citron, 2010; De Strooper
et al., 2010; Golde et al., 2011; Huang, 2006, 2010; Kim et al.,
2009; Mahley et al., 2006; Morris et al., 2011; Palop and Mucke,
2010). Nevertheless, some caveats deserve to be mentioned.
While dispersed cultures are well suited for studying cell-auton-
omous processes, they disrupt the intricate relationships that
exist among diverse cell types in the brain and can drastically
alter the activity of neurons and glia and their responses to
pathogens. In addition, it remains to be determined how best
to simulate brain aging in these models, which has such an
important impact on the development of AD and other neurode-
generative disorders.
These aspects of the human condition are more easily simu-
lated in animal models. Mice or rats genetically engineered to
express human APP/Ab, tau, apoE isoforms, a-synuclein, or
other AD-related factors in brain cells, either individually or in
combination, have been particularly informative. Some of the
insights provided by these models were highlighted in the text
above and many others were reviewed previously (Ashe and
Zahs, 2010; Huang, 2006, 2010; Ittner and Go¨tz, 2011; Jucker,
2010; Kim et al., 2009; Mahley et al., 2006; Marchetti and Marie,
2011; Morris et al., 2011; Palop and Mucke, 2010; Querfurth and
LaFerla, 2010). The following selection highlights but a few
examples.
Neuronal expression of hAPP carrying mutations that cause
autosomal dominant AD causes a range of AD-like abnormalities
in transgenic mice, including pathologically elevated levels of Ab
in brain, impairments of learning and memory, behavioral alter-
ations, synaptic deficits, aberrant network activity, alterations
in neuronal activity-dependent proteins, amyloid plaques,
neuritic dystrophy, vasculopathy, astrocytosis, andmicrogliosis.
Notably, several unexpected molecular alterations identified
in hAPP transgenic mice have been validated in the human
condition, including depletion of voltage-gated sodium channel
subunits in cortical interneurons (Verret et al., 2012), depletions
of calbindin and EphB2 in dentate granule cells (Cisse´ et al.,
2011; Palop et al., 2003), and hippocampal increases in meten-
kephalin, activated group IVA phospholipase A2, and collagen VI
(Cheng et al., 2009; Meilandt et al., 2008; Sanchez-Mejia et al.,
2008).
In spite of these striking similarities, several concerns have
been raised about the relevance of these models to the human
condition, in part because hAPP and Ab are overexpressed in
the mice but probably not in most cases of AD. However, over-
expression of hAPP and Ab also occurs in humans with APP
gene duplications, and this overexpression causes syndromes
that closely resemble sporadic AD (Rovelet-Lecrux et al.,
2006). Another concern raised about hAPP mice is that most
lines show little, if any, neuronal loss (Ashe and Zahs, 2010; Kar-
ran et al., 2011), a clear difference from the human condition.1216 Cell 148, March 16, 2012 ª2012 Elsevier Inc.This discrepancy might represent a true species difference but
might also suggest that Ab simply does not kill neurons in vivo
or that it requires longer to do so than the usual lifetime of
a mouse.
It has also been pointed out that none of the treatments that
have shown benefits in hAPP mice have so far shown benefits
in the human condition (Karran et al., 2011). As outlined above,
there are numerous reasons for drug failure in humans with AD
that have nothing to do with species barriers. It is also true that
the design of many preclinical trials is not rigorous enough and
sensible recommendations to rectify this problem have been
made (Jucker, 2010; Shineman et al., 2011). It should further
be noted in this context that most transgenic models aim to
evaluate specific pathogens in isolation, which is one of their
strengths but could clearly be a weakness in the assessment
of drugs for AD. Targeting a single factor in a multifactorial
pathogenic cascade may well result in detectable benefits
when this factor is isolated in an experimental model, but not
when it is accompanied by other copathogens in the complex
human condition.
Several reasons might account for why cognitive deficits
can be detected in hAPP mice before plaque formation and in
humans presumably only after plaque formation, including differ-
ences in the sensitivity of cognitive tests used, in the ability of
mice and humans to compensate for hippocampal deficits,
and in numerous variables that affect the deposition of Ab into
amyloid plaques or the formation of Ab oligomers. Formation
of plaques and Ab oligomers can be reliably dissociated only
in experimental models, where functional deficits have been
shown to be plaque-independent (Palop et al., 2006; Palop
and Mucke, 2010; Tomiyama et al., 2010).
Another concern is that the effect of murine apoE on Ab
metabolism clearly differs from human apoE, particularly with
respect to Ab deposition, which is more prominent in hAPP
transgenic mice expressing murine apoE than in those express-
ing human apoE isoforms (Bien-Ly et al., 2011; Holtzman et al.,
2000). Compared with mice lacking apoE, both human apoE3
and apoE4 stimulate Ab clearance in mice, whereas murine
apoE stimulates Ab deposition (Bien-Ly et al., 2011; Holtzman
et al., 2000). This difference has significant implications for
understanding the effect of apoE on Ab metabolism and for
validating and interpreting clinical trials of anti-Ab therapy. The
great majority of preclinical trials related to Ab were performed
in hAPP mice expressing endogenous murine apoE (Zahs and
Ashe, 2010). If murine apoE differs from human apoE in regu-
lating Ab metabolism, drugs that work well in hAPP mice with
murine apoE might not work well in AD patients with human
apoE. hAPP mice expressing different forms of human apoE
may have greater predictive value.
Conclusions and Outlook
There often are no simple solutions to complex problems and
AD is sadly a good case in point. Although progress in diverse
disciplines of science, technology, and medicine has helped
unravel many important aspects of this mysterious illness, the
field has yet to translate these insights into more effective treat-
ments for AD. We humbly submit the following suggestions as
to how this process might be accelerated. Premature clinical
trials should be avoided and scientific efforts intensified to
broaden and deepen the understanding of AD pathobiology.
More effective links should be established between basic
scientists and clinical investigators and between academia
and the pharmaceutical industry to expedite the discovery and
validation of potential drug targets and the development of
new therapeutics. Investigative and drug development efforts
should be diversified to fully address the multifactoriality of
the disease. It is likely that combination therapies with drugs
targeting different causal or modifying factors (e.g., Ab, tau,
and apoE4) will be most effective. Efforts to discover better
biomarkers should be continued and integrated with more inno-
vative approaches to clinical trial design. The extraordinary
potential of systems biology, personalized medicine, stem cell
technology and cell reprogramming should be brought to bear
on research and drug development for AD and related condi-
tions. To benefit from these steps before the predicted rise in
AD cases overwhelms health care systems around the world,
they would have to be implemented expeditiously and on a
broad scale. Concerted global efforts and substantial resources
will be required to make this happen.ACKNOWLEDGMENTS
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